Page last updated: 2024-08-25

rosiglitazone and Heart Failure

rosiglitazone has been researched along with Heart Failure in 80 studies

Research

Studies (80)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	45 (56.25)	29.6817
2010's	34 (42.50)	24.3611
2020's	1 (1.25)	2.80

Authors

Authors	Studies
Guo, ZF; He, WX; Huang, SQ; Huang, YJ; Jiang, LL; Li, B; Li, CJ; Li, SH; Song, XW; Su, T; Wu, H; Zhang, BL	1
Kolesnik, E; Resl, M; Sourij, H; von Lewinski, D; Wallner, M	1
Abassi, Z; Aronson, D; Feuerstein, GZ; Goltsman, I; Khoury, EE; Nativ, O; Winaver, J	1
Bach, RG; Brooks, MM; Donner, TW; Frye, RL; Garber, A; Genuth, S; Kelsey, SF; Kennedy, L; Lombardero, M; Monrad, ES; Pop-Busui, R	1
Chen, PC; Chen, RC; Hsu, CY; Lu, CJ; Muo, CH; Sun, Y	1
A Wahab, I; Kalisch, LM; Pratt, NL; Roughead, EE	1
Breunig, IM; McPherson, ML; Shaya, FT; Snitker, S	1
Dangi-Garimella, S	1
Carmosino, M; Gerbino, A; Mastrofrancesco, L; Milano, S; Nicoletti, MC; Procino, G; Svelto, M	1
Chan, EW; Choi, NK; Griffiths, J; Kimura, M; Kimura, T; Kubota, K; Lai, EC; Man, KK; Nguyen, TA; Ooba, N; Park, BJ; Pratt, NL; Roughead, EE; Sato, T; Shin, JY; Wang, T; Wong, IC; Yang, YH	1
Abdullah, SM; Ayers, CR; de Lemos, JA; Gore, MO; Grinsfelder, DB; Khera, A; McGuire, DK; Neeland, IJ; Pandey, A; Salahuddin, UI; See, R	1
Bhoi, B; Gatne, MM; Giri, SR; Jain, MR	1
Cobitz, A; Heise, M; Koch, G; Louridas, B; McMorn, S; Semigran, M; Sowell, M; Zambanini, A	1
Kenny, C	1
Lasaridis, AN; Sarafidis, PA; Stafylas, PC	1
Furberg, CD; Singh, S	1
Loke, YK; Singh, S	1
Mannucci, E; Marchionni, N; Monami, M	1
Levin, R; Setoguchi, S; Solomon, DH; Winkelmayer, WC	1
Parashar, A	1
Arrigain, S; Atreja, A; Jain, A; Kattan, MW; Pantalone, KM; Wells, BJ; Yu, C; Zimmerman, RS	1
Blackburn, DF; Eurich, DT; Johnson, JA; Lamb, DA; Leung, AA; Majumdar, SR; McAlister, FA	1
Sinclair, A; Viljoen, A	1
Beck-Nielsen, H; Curtis, PS; Gomis, R; Hanefeld, M; Home, PD; Jones, NP; Komajda, M; McMurray, JJ; Pocock, SJ	2
Baader, M; Breitschopf, K; Falk, E; Gerl, M; Kramer, W; Linz, W; Rütten, H; Schäfer, HL; Wohlfart, P	1
Hobbs, FD; Taylor, C	1
Austin, PC; Gomes, T; Hux, JE; Juurlink, DN; Lipscombe, LL; Mamdani, MM	1
de Vries, CS; Russell-Jones, DL	1
Booth, A; Konstantinidis, A; Lambley, RG; Vahdani, K	1
Curcin, V; Elliott, P; Hughes, RI; Khunti, K; Little, MP; Majeed, A; Millett, CJ; Molokhia, M; Ng, A; Tzoulaki, I; Wilkins, MR	1
Nissen, SE	2
Asghari, S; Carpentier, AC; Courteau, J; Vanasse, A	1
Açar, G; Akçakoyun, M; Esen, AM; Esen, O; Kahveci, G; Karaahmet, T; Kargin, R; Kirma, C; Pala, S; Tigen, K	1
Bolger, AF; Eckel, RH; Giugliano, RP; Herrington, D; Kaul, S	1
Dushinat, M; Friedman, N; Halkin, H; Katzir, I; Kokia, E; Kurnik, D; Loebstein, R; Lomnicky, Y; Silverman, B; Vesterman-Landes, J	1
Slaoui, M	1
Abassi, Z; Collins-Racie, L; Diblasio-Smith, L; Feuerstein, GZ; Goltsman, I; Lavallie, ER; Liu, X; Mounts, WM; Rutkowski, JL; Wang, X; Winaver, J; Xu, X; Zhan, Y	1
Juurlink, DN	1
Ali, F; Graham, DJ; Kelman, JA; MaCurdy, TE; Ouellet-Hellstrom, R; Sholley, C; Worrall, C	1
Bohn, RL; Chang, CL; Cziraky, MJ; Sarawate, CA; Wertz, DA; Willey, VJ	1
Masoudi, FA	1
Lipska, KJ; Ross, JS	1
Abassi, Z; Diblasio-Smith, EA; Feuerstein, GZ; Goltsman, I; Hoffman, A; Lavallie, ER; Ovcharenko, E; Wang, X; Winaver, J	1
Kwok, CS; Loke, YK; Singh, S	1
Abdullah, SM; Armstead, SI; Ayers, CR; de Lemos, JA; Gore, MO; Khera, A; McGavock, J; McGuire, DK; Narang, N; See, R; Snell, PG; Stream, A	1
Berthet, S; Lapeyre-Mestre, M; Montastruc, JL; Olivier, P	1
Chang, YW; Chen, WL; Chou, CC; Kao, TW; Loh, CH; Wang, CC	1
Wang, X	1
Gallagher, AM; Leufkens, HG; Seabroke, S; Smeeth, L; van Staa, TP	1
Aimaretti, G; Cittadini, A; Isgaard, J; Longobardi, S; Monti, MG; Napoli, R; Netti, PA; Rea, D; Saccà, L; Samà, M; Walser, M	1
Khalaf, KI; Taegtmeyer, H	1
Pouwels, KB; van Grootheest, K	1
Apolito, RA	1
Clarke, K; Cole, MA; Hulbert, K; Lygate, CA; Monfared, M; Neubauer, S	1
Gozansky, WS; Page, RL; Ruscin, JM	1
Buse, JB	1
Papoushek, C	1
Singh, N	1
Le Feuvre, C	1
Bultemeier, NC; Hartung, DM; Haxby, DG; Touchette, DR	1
Edwards, KL; Greene, RS; Irons, BK; Mazzolini, TA; Sleeper, RB	1
Beck-Nielsen, H; Gomis, R; Hanefeld, M; Home, PD; Jones, NP; Komajda, M; McMurray, JJ; Pocock, SJ	1
Nathan, DM	1
Isom, R; Kiryluk, K	1
Lago, RM; Nesto, RW; Singh, PP	1
Comarow, A	1
Stroup, JS	1
Alter, DA; Gomes, T; Hux, JE; Juurlink, DN; Lévesque, LE; Lipscombe, LL	1
D'Arrigo, T	1
Goldfine, AB	1
Dahabreh, IJ; Economopoulos, K	1
Achtari Jeanneret, L; Barras-Moret, AC; Carron, P; Deriaz-Chessex, S; Donzé, J; Fournier, Y; Gachoud, D; Moix, PA; Monti, M; Rossier, A; Wilson, P	1
Benbow, A; Stewart, M; Yeoman, G	1
Wooltorton, E	1
Groop, L; Ridderstråle, M	1
Scheen, AJ	1

Reviews

17 review(s) available for rosiglitazone and Heart Failure

Article	Year
New Antihyperglycemic Drugs and Heart Failure: Synopsis of Basic and Clinical Data. BioMed research international, 2017, Volume: 2017 Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycemic Agents; Myocardial Infarction; Rosiglitazone; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones	2017
Rosiglitazone and the thiazolidinediones: a changing context. Primary care diabetes, 2007, Volume: 1, Issue:4 Topics: Fractures, Bone; Heart Failure; Humans; Hypoglycemic Agents; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones	2007
The controversial effects of thiazolidinediones on cardiovascular morbidity and mortality. International journal of cardiology, 2009, Jan-24, Volume: 131, Issue:3 Topics: Animals; Cardiovascular Diseases; Cardiovascular System; Edema; Heart Failure; Humans; Pioglitazone; PPAR gamma; Risk Factors; Rosiglitazone; Secondary Prevention; Thiazolidinediones	2009
The safety of rosiglitazone in the treatment of type 2 diabetes. Expert opinion on drug safety, 2008, Volume: 7, Issue:5 Topics: Blood Glucose; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Fractures, Bone; Heart Failure; Humans; Hypoglycemic Agents; Myocardial Infarction; Risk Factors; Rosiglitazone; Thiazolidinediones	2008
Winners and losers at the rosiglitazone gamble A meta-analytical approach at the definition of the cardiovascular risk profile of rosiglitazone. Diabetes research and clinical practice, 2008, Volume: 82, Issue:1 Topics: Aged; Body Mass Index; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Heart Failure; Humans; Hypoglycemic Agents; Male; Middle Aged; Myocardial Infarction; Randomized Controlled Trials as Topic; Risk Factors; Rosiglitazone; Thiazolidinediones; Triglycerides	2008
Safety and efficacy of rosiglitazone in the elderly diabetic patient. Vascular health and risk management, 2009, Volume: 5, Issue:1 Topics: Age Factors; Aged; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Fractures, Bone; Heart Failure; Humans; Hypoglycemic Agents; Myocardial Ischemia; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Risk Assessment; Risk Factors; Rosiglitazone; Thiazolidinediones; Treatment Outcome	2009
Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. BMJ (Clinical research ed.), 2011, Mar-17, Volume: 342 Topics: Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycemic Agents; Myocardial Infarction; Pioglitazone; Prognosis; Publication Bias; Risk Factors; Rosiglitazone; Thiazolidinediones	2011
Assessment of cardiac safety for PPARγ agonists in rodent models of heart failure: a translational medicine perspective. Current molecular pharmacology, 2012, Volume: 5, Issue:2 Topics: Animals; Biomarkers; Diabetes Mellitus, Experimental; Disease Models, Animal; Gene Expression Profiling; Heart Failure; Hypoglycemic Agents; Kidney; Myocardial Infarction; PPAR gamma; Rosiglitazone; Thiazolidinediones; Translational Research, Biomedical	2012
After avandia: the use of antidiabetic drugs in patients with heart failure. Texas Heart Institute journal, 2012, Volume: 39, Issue:2 Topics: Blood Glucose; Comorbidity; Diabetes Mellitus, Type 2; Gluconeogenesis; Glycated Hemoglobin; Heart Failure; Humans; Hypoglycemic Agents; Insulin Resistance; Liver; Myocardium; Risk Assessment; Risk Factors; Rosiglitazone; Thiazolidinediones; Treatment Outcome	2012
Possible heart failure exacerbation associated with rosiglitazone: case report and literature review. Pharmacotherapy, 2003, Volume: 23, Issue:7 Topics: Aged; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycemic Agents; Male; Rosiglitazone; Thiazolidinediones	2003
The "glitazones": rosiglitazone and pioglitazone. Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC, 2003, Volume: 25, Issue:10 Topics: Contraindications; Diabetes Mellitus, Type 2; Drug Interactions; Female; Heart Failure; Humans; Hypoglycemic Agents; Lactation; Pioglitazone; Pregnancy; Risk Factors; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Weight Gain	2003
[Cardiovascular effects of rosiglitazone]. Presse medicale (Paris, France : 1983), 2004, Jun-19, Volume: 33, Issue:11 Topics: Cardiovascular Diseases; Cardiovascular System; Cause of Death; Diabetes Mellitus, Type 2; Drug Monitoring; Edema; France; Heart Failure; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Morbidity; Primary Prevention; Research Design; Risk Factors; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Vasodilator Agents	2004
Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus. Pharmacotherapy, 2006, Volume: 26, Issue:2 Topics: Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycemic Agents; Pioglitazone; Risk Assessment; Rosiglitazone; Thiazolidinediones; Treatment Outcome	2006
Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet (London, England), 2007, Sep-29, Volume: 370, Issue:9593 Topics: Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Randomized Controlled Trials as Topic; Risk Factors; Rosiglitazone; Thiazolidinediones	2007
The rough road for rosiglitazone. Current opinion in endocrinology, diabetes, and obesity, 2008, Volume: 15, Issue:2 Topics: Cardiovascular Diseases; Diabetes Mellitus; Heart Failure; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Risk Factors; Rosiglitazone; Thiazolidinediones; Time Factors	2008
Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone. Clinical trials (London, England), 2008, Volume: 5, Issue:2 Topics: Cardiovascular Diseases; Heart Failure; Humans; Hypoglycemic Agents; Myocardial Infarction; Randomized Controlled Trials as Topic; Risk Factors; Rosiglitazone; Thiazolidinediones	2008
[Medication of the month. Rosiglitazone (Avandia)]. Revue medicale de Liege, 2002, Volume: 57, Issue:4 Topics: Administration, Oral; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Liver; Prognosis; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones; Weight Gain	2002

Trials

7 trial(s) available for rosiglitazone and Heart Failure

Article	Year
Rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Circulation, 2013, Aug-20, Volume: 128, Issue:8 Topics: Aged; Angioplasty; Comorbidity; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Heart Failure; Humans; Hypoglycemic Agents; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Retrospective Studies; Risk Factors; Rosiglitazone; Stroke; Thiazolidinediones; Treatment Outcome	2013
Effect of treatment with rosiglitazone on high-sensitivity cardiac troponin levels among patients with type 2 diabetes mellitus. Diabetes & vascular disease research, 2016, Volume: 13, Issue:2 Topics: Adult; Aged; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Hypoglycemic Agents; Male; Middle Aged; Myocardial Infarction; Risk Factors; Rosiglitazone; Thiazolidinediones; Troponin	2016
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet (London, England), 2009, Jun-20, Volume: 373, Issue:9681 Topics: Administration, Oral; Angina, Unstable; Body Weight; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diuretics; Drug Therapy, Combination; Drug Utilization; Female; Fractures, Bone; Glycated Hemoglobin; Heart Failure; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Metformin; Middle Aged; Myocardial Infarction; Neoplasms; Prospective Studies; Rosiglitazone; Sex Factors; Stroke; Sulfonylurea Compounds; Thiazolidinediones	2009
Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. European heart journal, 2010, Volume: 31, Issue:7 Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Hypoglycemic Agents; Kaplan-Meier Estimate; Male; Middle Aged; Risk Factors; Rosiglitazone; Thiazolidinediones	2010
Rosiglitazone, but not pioglitazone, improves myocardial systolic function in type 2 diabetic patients: a tissue Doppler study. Echocardiography (Mount Kisco, N.Y.), 2010, Volume: 27, Issue:5 Topics: Blood Pressure; Cardiovascular System; Diabetes Mellitus, Type 2; Echocardiography, Doppler; Female; Heart Failure; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Rosiglitazone; Systole; Thiazolidinediones	2010
Assessment of cardiac structure and function in patients without and with peripheral oedema during rosiglitazone treatment. Diabetes & vascular disease research, 2011, Volume: 8, Issue:2 Topics: Aged; Biomarkers; Chi-Square Distribution; Diabetes Mellitus, Type 2; Edema; Exercise Test; Female; Heart Failure; Hematocrit; Humans; Hypoglycemic Agents; Magnetic Resonance Imaging; Male; Middle Aged; Myocardium; Natriuretic Peptide, Brain; Oxygen Consumption; Plasma Volume; Prospective Studies; Rosiglitazone; Serum Albumin; Single-Blind Method; Stroke Volume; Texas; Thiazolidinediones; Time Factors; Ventricular Function; Weight Gain	2011
Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis. The New England journal of medicine, 2007, Jul-05, Volume: 357, Issue:1 Topics: Adult; Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Hypoglycemic Agents; Kaplan-Meier Estimate; Male; Metformin; Middle Aged; Myocardial Infarction; Risk; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones	2007

Other Studies

56 other study(ies) available for rosiglitazone and Heart Failure

Article	Year
Abnormal expression of PRKAG2-AS results in dysfunction of cardiomyocytes through regulating PRKAG2 transcription by interacting with PPARG. Clinical epigenetics, 2023, Nov-07, Volume: 15, Issue:1 Topics: AMP-Activated Protein Kinases; Apoptosis; DNA Methylation; Heart Failure; Humans; Hypoxia; In Situ Hybridization, Fluorescence; Myocardial Ischemia; Myocytes, Cardiac; PPAR gamma; RNA, Long Noncoding; Rosiglitazone	2023
Rosiglitazone treatment restores renal responsiveness to atrial natriuretic peptide in rats with congestive heart failure. Journal of cellular and molecular medicine, 2019, Volume: 23, Issue:7 Topics: Acetylcholine; Animals; Atrial Natriuretic Factor; Blood Pressure; Cyclic GMP; Endothelium; Gene Expression Regulation; Heart Failure; Hemodynamics; Kidney; Male; Rats, Sprague-Dawley; Rosiglitazone; Signal Transduction; Vasodilation	2019
Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study. Cerebrovascular diseases (Basel, Switzerland), 2013, Volume: 36, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cohort Studies; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Hypoglycemic Agents; Incidence; Male; Middle Aged; Pioglitazone; Risk; Rosiglitazone; Stroke; Thiazolidinediones; Young Adult	2013
Comparing time to adverse drug reaction signals in a spontaneous reporting database and a claims database: a case study of rofecoxib-induced myocardial infarction and rosiglitazone-induced heart failure signals in Australia. Drug safety, 2014, Volume: 37, Issue:1 Topics: Adverse Drug Reaction Reporting Systems; Australia; Bayes Theorem; Cyclooxygenase 2 Inhibitors; Databases, Factual; Heart Failure; Humans; Hypoglycemic Agents; Lactones; Myocardial Infarction; Neural Networks, Computer; Product Surveillance, Postmarketing; Rosiglitazone; Sulfones; Thiazolidinediones; Time Factors	2014
Development of heart failure in Medicaid patients with type 2 diabetes treated with pioglitazone, rosiglitazone, or metformin. Journal of managed care & specialty pharmacy, 2014, Volume: 20, Issue:9 Topics: Adolescent; Adult; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Fee-for-Service Plans; Female; Follow-Up Studies; Heart Failure; Humans; Hypoglycemic Agents; Incidence; Male; Managed Care Programs; Maryland; Medicaid; Metformin; Middle Aged; Pioglitazone; Retrospective Studies; Risk Factors; Rosiglitazone; Survival Analysis; Thiazolidinediones; United States; Young Adult	2014
The Yin and the Yang of CV risks in patients with diabetes. The American journal of managed care, 2014, Volume: 20, Issue:8 Spec No. Topics: Adamantane; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Drug-Related Side Effects and Adverse Reactions; Heart Failure; Heart Rate; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Myocardial Infarction; Pioglitazone; Risk Assessment; Rosiglitazone; Safety-Based Drug Withdrawals; Stroke; Thiazolidinediones; United States; United States Food and Drug Administration	2014
Rosiglitazone promotes AQP2 plasma membrane expression in renal cells via a Ca-dependent/cAMP-independent mechanism. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2015, Volume: 35, Issue:3 Topics: Aquaporin 2; Calcium Channels; Calcium Signaling; Cell Line; Cell Membrane; Cyclic AMP; Edema; Endocytosis; Epithelial Cells; Gene Expression; Heart Failure; Humans; Kidney; Rosiglitazone; Signal Transduction; Thiazolidinediones; TRPV Cation Channels; Vasopressins	2015
Variation in Association Between Thiazolidinediones and Heart Failure Across Ethnic Groups: Retrospective analysis of Large Healthcare Claims Databases in Six Countries. Drug safety, 2015, Volume: 38, Issue:9 Topics: Databases, Factual; Edema; Ethnicity; Furosemide; Heart Failure; Hospitalization; Humans; Pioglitazone; Polymorphism, Genetic; Retrospective Studies; Rosiglitazone; Thiazolidinediones	2015
Cardioprotective role of peroxisome proliferator-activated receptor-γ agonist, rosiglitazone in a unique murine model of diabetic cardiopathy. Life sciences, 2016, Oct-01, Volume: 162 Topics: Animals; Aorta; Diabetes Complications; Disease Models, Animal; Gene Expression; Heart Failure; Hypoglycemic Agents; Kidney; Mice; Myocardium; PPAR gamma; Rats; Rats, Zucker; Rosiglitazone; Thiazolidinediones	2016
A retrospective evaluation of congestive heart failure and myocardial ischemia events in 14,237 patients with type 2 diabetes mellitus enrolled in 42 short-term, double-blind, randomized clinical studies with rosiglitazone. Pharmacoepidemiology and drug safety, 2008, Volume: 17, Issue:8 Topics: Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Heart Failure; Humans; Hypoglycemic Agents; Male; Middle Aged; Myocardial Ischemia; Odds Ratio; Randomized Controlled Trials as Topic; Retrospective Studies; Rosiglitazone; Thiazolidinediones; Time Factors	2008
Thiazolidinediones and cardiovascular outcomes in type 2 diabetes. Heart (British Cardiac Society), 2009, Volume: 95, Issue:1 Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Heart Failure; Humans; Myocardial Ischemia; Pioglitazone; Rosiglitazone; Thiazolidinediones; Treatment Outcome	2009
Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy. Archives of internal medicine, 2008, Nov-24, Volume: 168, Issue:21 Topics: Aged; Diabetes Complications; Diabetes Mellitus; Female; Heart Failure; Humans; Hypoglycemic Agents; Male; Myocardial Infarction; Pioglitazone; Rosiglitazone; Stroke; Thiazolidinediones; Treatment Outcome	2008
N-3 polyunsaturated fatty acids and statins in heart failure. Lancet (London, England), 2009, Jan-31, Volume: 373, Issue:9661 Topics: Diabetes Complications; Diabetes Mellitus; Fatty Acids, Unsaturated; Heart Failure; Humans; Hypoglycemic Agents; Rosiglitazone; Thiazolidinediones	2009
The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis. Acta diabetologica, 2009, Volume: 46, Issue:2 Topics: Angiotensin-Converting Enzyme Inhibitors; Coronary Artery Bypass; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Heart Failure; Humans; Hypoglycemic Agents; Male; Metformin; Multivariate Analysis; Proportional Hazards Models; Retrospective Studies; Risk Factors; Rosiglitazone; Smoking; Sulfonylurea Compounds; Survival Analysis; Survivors; Thiazolidinediones	2009
Risk of heart failure in patients with recent-onset type 2 diabetes: population-based cohort study. Journal of cardiac failure, 2009, Volume: 15, Issue:2 Topics: Aged; Cohort Studies; Confidence Intervals; Databases as Topic; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Hypoglycemic Agents; Incidence; Male; Middle Aged; Risk; Risk Factors; Rosiglitazone; Sex Factors; Thiazolidinediones; Time Factors	2009
The peroxisome proliferator-activated receptor-alpha (PPAR-alpha) agonist, AVE8134, attenuates the progression of heart failure and increases survival in rats. Acta pharmacologica Sinica, 2009, Volume: 30, Issue:7 Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Benzoates; Biomarkers; Cardiotonic Agents; Cell Line; Disease Progression; Heart Failure; Hemodynamics; Humans; Hypoglycemic Agents; Male; Molecular Structure; Nitric Oxide Synthase Type III; Oxazoles; PPAR alpha; Ramipril; Rats; Rats, Inbred SHR; Rats, Sprague-Dawley; Rosiglitazone; Survival Rate; Thiazolidinediones	2009
Type 2 diabetes, thiazolidinediones, and cardiovascular risk. The British journal of general practice : the journal of the Royal College of General Practitioners, 2009, Volume: 59, Issue:564 Topics: Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Pioglitazone; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Risk Factors; Rosiglitazone; Thiazolidinediones	2009
Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study. BMJ (Clinical research ed.), 2009, Aug-18, Volume: 339 Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Hypoglycemic Agents; Male; Myocardial Infarction; Pioglitazone; Retrospective Studies; Risk Factors; Rosiglitazone; Thiazolidinediones; Treatment Outcome	2009
Rosiglitazone or pioglitazone in type 2 diabetes? BMJ (Clinical research ed.), 2009, Aug-18, Volume: 339 Topics: Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycemic Agents; Myocardial Infarction; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones	2009
Rosiglitazone and pioglitazone. Beware macular oedema. BMJ (Clinical research ed.), 2009, Sep-22, Volume: 339 Topics: Diabetic Angiopathies; Diabetic Nephropathies; Heart Failure; Humans; Hypoglycemic Agents; Macular Edema; Pioglitazone; Rosiglitazone; Thiazolidinediones	2009
Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ (Clinical research ed.), 2009, Dec-03, Volume: 339 Topics: Administration, Oral; Aged; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Fractures, Bone; Heart Failure; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Myocardial Infarction; Pioglitazone; Retrospective Studies; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones	2009
The rise and fall of rosiglitazone. European heart journal, 2010, Volume: 31, Issue:7 Topics: Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycemic Agents; Rosiglitazone; Thiazolidinediones	2010
Stroke and cardiovascular morbidity and mortality associated with rosiglitazone use in elderly diabetic patients. Diabetes & vascular disease research, 2009, Volume: 6, Issue:2 Topics: Age Factors; Aged; Aged, 80 and over; Case-Control Studies; Diabetes Mellitus; Drug Prescriptions; Heart Failure; Hospitalization; Humans; Hypoglycemic Agents; Logistic Models; Myocardial Infarction; Odds Ratio; Quebec; Registries; Retrospective Studies; Risk Assessment; Risk Factors; Rosiglitazone; Stroke; Thiazolidinediones; Treatment Outcome	2009
Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College Of Cardiology Foundation. Journal of the American College of Cardiology, 2010, Apr-27, Volume: 55, Issue:17 Topics: American Heart Association; Cardiology; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycemic Agents; Myocardial Ischemia; Pioglitazone; Rosiglitazone; Societies, Medical; Thiazolidinediones; United States	2010
The painful truth. European heart journal, 2010, Volume: 31, Issue:10 Topics: Access to Information; Cholesterol, LDL; Diabetes Mellitus; Drug Industry; Heart Failure; Hypoglycemic Agents; Meta-Analysis as Topic; Myocardial Ischemia; Rosiglitazone; Safety-Based Drug Withdrawals; Thiazolidinediones; United States; United States Food and Drug Administration	2010
Database evaluation of the effects of long-term rosiglitazone treatment on cardiovascular outcomes in patients with type 2 diabetes. Journal of clinical pharmacology, 2011, Volume: 51, Issue:2 Topics: Aged; Cardiovascular Diseases; Databases, Factual; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Heart Failure; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Retrospective Studies; Rosiglitazone; Thiazolidinediones	2011
The rise and fall of rosiglitazone: reply. European heart journal, 2010, Volume: 31, Issue:10 Topics: Cholesterol, LDL; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycemic Agents; Rosiglitazone; Thiazolidinediones	2010
Pharmacogenomic, physiological, and biochemical investigations on safety and efficacy biomarkers associated with the peroxisome proliferator-activated receptor-gamma activator rosiglitazone in rodents: a translational medicine investigation. The Journal of pharmacology and experimental therapeutics, 2010, Sep-01, Volume: 334, Issue:3 Topics: Animals; Biomarkers; Body Weight; Diabetes Mellitus; Echocardiography; Fibrosis; Gene Expression Regulation; Heart Failure; Hemodynamics; Hypoglycemic Agents; Immunohistochemistry; Myocarditis; Myocardium; Organ Size; PPAR gamma; Rats; Rats, Inbred Lew; Rats, Zucker; RNA; Rosiglitazone; Thiazolidinediones; Translational Research, Biomedical	2010
Rosiglitazone and the case for safety over certainty. JAMA, 2010, Jul-28, Volume: 304, Issue:4 Topics: Decision Making; Diabetes Mellitus, Type 2; Heart Failure; Hypoglycemic Agents; Meta-Analysis as Topic; Myocardial Infarction; Pioglitazone; Risk; Rosiglitazone; Thiazolidinediones	2010
Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA, 2010, Jul-28, Volume: 304, Issue:4 Topics: Aged; Aged, 80 and over; Cohort Studies; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Hypoglycemic Agents; Incidence; Male; Medicare Part D; Myocardial Infarction; Pioglitazone; Retrospective Studies; Risk; Rosiglitazone; Stroke; Thiazolidinediones; United States	2010
Risk of cardiovascular events and all-cause mortality in patients treated with thiazolidinediones in a managed-care population. Circulation. Cardiovascular quality and outcomes, 2010, Volume: 3, Issue:5 Topics: Female; Heart Failure; Humans; Male; Managed Care Programs; Middle Aged; Myocardial Infarction; Pioglitazone; Population Groups; Retrospective Studies; Risk Assessment; Rosiglitazone; Survival Analysis; Thiazolidinediones; United States	2010
Improving drug safety surveillance: lessons from rosiglitazone. Circulation. Cardiovascular quality and outcomes, 2010, Volume: 3, Issue:5 Topics: Clinical Trials as Topic; Heart Failure; Humans; Managed Care Programs; Myocardial Infarction; Quality Assurance, Health Care; Risk; Rosiglitazone; Survival Analysis; Thiazolidinediones; United States	2010
Switching from rosiglitazone: thinking outside the class. JAMA, 2011, Feb-23, Volume: 305, Issue:8 Topics: Blood Glucose; Cardiovascular Diseases; Decision Making; Diabetes Mellitus; Drug Labeling; Evidence-Based Medicine; Heart Failure; Humans; Hypoglycemic Agents; Pioglitazone; Risk; Rosiglitazone; Thiazolidinediones	2011
Effects of chronic rosiglitazone treatment on renal handling of salt and water in rats with volume-overload congestive heart failure. Circulation. Heart failure, 2011, Volume: 4, Issue:3 Topics: Animals; Disease Models, Animal; Heart Failure; Kidney Function Tests; Male; Rats; Rats, Sprague-Dawley; Rosiglitazone; Sodium Chloride; Thiazolidinediones; Water; Water-Electrolyte Balance; Water-Electrolyte Imbalance	2011
Drug safety of rosiglitazone and pioglitazone in France: a study using the French PharmacoVigilance database. BMC clinical pharmacology, 2011, May-24, Volume: 11 Topics: Adult; Aged; Chemical and Drug Induced Liver Injury; Databases, Factual; Diabetes Mellitus, Type 2; Edema; Female; France; Heart Failure; Humans; Hypoglycemic Agents; Male; Middle Aged; Myocardial Infarction; Pioglitazone; Rosiglitazone; Thiazolidinediones	2011
Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population. Clinical therapeutics, 2011, Volume: 33, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Antihypertensive Agents; Cardiovascular Diseases; Cerebrovascular Disorders; Chi-Square Distribution; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Incidence; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Pioglitazone; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Risk Factors; Rosiglitazone; Taiwan; Thiazolidinediones; Time Factors; Treatment Outcome	2011
Risk of death and cardiovascular outcomes with thiazolidinediones: a study with the general practice research database and secondary care data. PloS one, 2011, Volume: 6, Issue:12 Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Cardiovascular Diseases; Cohort Studies; Databases, Factual; Diabetes Complications; Diabetes Mellitus; Female; Heart Failure; Hospitalization; Humans; Insulin; Male; Metformin; Middle Aged; Pioglitazone; Risk; Rosiglitazone; Stroke; Thiazolidinediones; Treatment Outcome	2011
Metformin prevents the development of chronic heart failure in the SHHF rat model. Diabetes, 2012, Volume: 61, Issue:4 Topics: Animals; Blood Glucose; Blood Pressure; Chronic Disease; Gene Expression Regulation; Heart Failure; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Rats; Rats, Inbred SHR; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Ventricular Remodeling	2012
The rosiglitazone decision process at FDA and EMA. What should we learn? The International journal of risk & safety in medicine, 2012, Volume: 24, Issue:2 Topics: Contraindications; Diabetes Mellitus, Type 2; Drug Approval; Drug Synergism; Drug Therapy, Combination; Europe; European Union; Guidelines as Topic; Heart Failure; Humans; Hypoglycemic Agents; Insulin; Meta-Analysis as Topic; Myocardial Ischemia; Risk Assessment; Rosiglitazone; Safety-Based Drug Withdrawals; Thiazolidinediones; United States; United States Food and Drug Administration	2012
Initial management of glycemia in type 2 diabetes. The New England journal of medicine, 2003, Feb-20, Volume: 348, Issue:8 Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Heart Failure; Humans; Hypoglycemic Agents; Insulin; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones	2003
The PPARgamma-activator rosiglitazone does not alter remodeling but increases mortality in rats post-myocardial infarction. Cardiovascular research, 2003, Jun-01, Volume: 58, Issue:3 Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Cardiotonic Agents; Drug Therapy, Combination; Echocardiography; Heart Failure; Male; Myocardial Infarction; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazolidinediones; Transcription Factors; Treatment Failure; Ventricular Remodeling	2003
Glitazones and heart failure: critical appraisal for the clinician. Circulation, 2003, Aug-26, Volume: 108, Issue:8 Topics: Anti-Inflammatory Agents, Non-Steroidal; Calcium Channel Blockers; Diuretics; Edema; Heart Failure; Humans; Hypoglycemic Agents; Insulin; Pioglitazone; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones	2003
Protecting the heart while controlling blood sugar. New guidelines help define and refine the use of two diabetes drugs that could be a boon for people who also have heart disease. Harvard heart letter : from Harvard Medical School, 2004, Volume: 14, Issue:7 Topics: Contraindications; Diabetes Mellitus; Diabetic Angiopathies; Heart Diseases; Heart Failure; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazolidinediones	2004
Rosiglitazone and heart failure: long-term vigilance. Journal of cardiovascular pharmacology and therapeutics, 2004, Volume: 9, Issue:1 Topics: Aged; Diabetes Mellitus; Edema; Heart Failure; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Middle Aged; Rosiglitazone; Thiazolidinediones; Time Factors	2004
Risk of hospitalization for heart failure associated with thiazolidinedione therapy: a medicaid claims-based case-control study. Pharmacotherapy, 2005, Volume: 25, Issue:10 Topics: Adult; Aged; Case-Control Studies; Chromans; Diabetes Mellitus, Type 2; Female; Heart Failure; Hospitalization; Humans; Hypoglycemic Agents; Male; Medicaid; Middle Aged; Pioglitazone; Retrospective Studies; Risk; Rosiglitazone; Thiazolidinediones; Troglitazone	2005
Rosiglitazone and cardiotoxicity--weighing the evidence. The New England journal of medicine, 2007, Jul-05, Volume: 357, Issue:1 Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Heart Failure; Humans; Hypoglycemic Agents; Metformin; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones	2007
Thiazolidinediones and cardiovascular disease. The Medical letter on drugs and therapeutics, 2007, Jul-16, Volume: 49, Issue:1265 Topics: Animals; Heart Failure; Humans; Hypoglycemic Agents; Myocardial Infarction; Pioglitazone; Rosiglitazone; Thiazolidinediones	2007
Thiazolidinediones and fluid retention. Kidney international, 2007, Volume: 72, Issue:6 Topics: Aged; Blood Volume; Diabetes Mellitus, Type 2; Edema; Female; Heart Failure; Humans; Hypoglycemic Agents; Kidney; Rosiglitazone; Thiazolidinediones	2007
Avandia in perspective. U.S. news & world report, 2007, Oct-01, Volume: 143, Issue:11 Topics: Blood Glucose; Diabetes Mellitus; Exercise; Health Behavior; Heart Failure; Humans; Hypoglycemic Agents; Myocardial Infarction; Obesity; Risk-Taking; Rosiglitazone; Thiazolidinediones; United States	2007
Thiazolidinedione-induced edema in patients with heart failure. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2007, Dec-01, Volume: 64, Issue:23 Topics: Diabetes Mellitus, Type 2; Edema; Heart Failure; Humans; Hypoglycemic Agents; Risk Assessment; Rosiglitazone; Thiazolidinediones	2007
Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA, 2007, Dec-12, Volume: 298, Issue:22 Topics: Aged; Aged, 80 and over; Cause of Death; Diabetes Mellitus; Female; Heart Failure; Humans; Hypoglycemic Agents; Male; Myocardial Infarction; Pioglitazone; Retrospective Studies; Risk; Rosiglitazone; Thiazolidinediones	2007
Glitazones and your heart, revisited. Diabetes forecast, 2007, Volume: 60, Issue:13 Topics: Heart Diseases; Heart Failure; Humans; Pioglitazone; Rosiglitazone; Thiazolidinediones	2007
[Highlights 2007 in hospital-based internal medicine: the point of view from the chief residents]. Revue medicale suisse, 2008, Jan-30, Volume: 4, Issue:142 Topics: Accidental Falls; Aged; Albuterol; Anemia; Anticoagulants; Antidiuretic Hormone Receptor Antagonists; Atrial Fibrillation; Attitude of Health Personnel; Benzazepines; Bronchitis, Chronic; Bronchodilator Agents; Cardiac Pacing, Artificial; Diabetes Mellitus; Endocarditis, Bacterial; Erythropoietin; Heart Failure; Heparin; Humans; Internal Medicine; Interprofessional Relations; Medical Staff, Hospital; Myocardial Infarction; Recombinant Proteins; Risk Management; Rosiglitazone; Salmeterol Xinafoate; Thiazolidinediones; Thromboembolism; Tolvaptan; Vasodilator Agents; Ventricular Dysfunction, Left; Workload	2008
Thiazolidinediones for type 2 diabetes. All glitazones may exacerbate heart failure. BMJ (Clinical research ed.), 2001, Jan-27, Volume: 322, Issue:7280 Topics: Heart Failure; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones	2001
Rosiglitazone (Avandia) and pioglitazone (Actos) and heart failure. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2002, Jan-22, Volume: 166, Issue:2 Topics: Heart Failure; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones	2002
[A case report. Rosiglitazone treatment was highly effective yet had to be terminated]. Lakartidningen, 2002, Jan-31, Volume: 99, Issue:5 Topics: Administration, Oral; Contraindications; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Heart Failure; Humans; Hypoglycemic Agents; Insulin; Middle Aged; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome	2002